Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

2.900 +0.120 (+4.32%)
Streaming Delayed Price Updated: 3:53 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,714
Open 2.700
Bid (Size) 2.850 (1)
Ask (Size) 2.900 (96)
Prev. Close 2.780
Today's Range 2.700 - 3.190
52wk Range 1.950 - 7.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the US, Australia and Japan 
Via Benzinga
Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested
On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA. 
Via Benzinga

Performance

YTD
-56.91%
-56.91%
1 Month
-8.80%
-8.80%
3 Month
-41.41%
-41.41%
6 Month
-57.35%
-57.35%
1 Year
-57.35%
-57.35%

More News

Read More
23 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
The Hidden Potential Of The Endocannabinoid System? SciSparc Says Its Portfolio Of Cannabinoids-Derived Drug Candidates Tap The Body's Natural System
Via Benzinga
SciSparc Files Annual Report For Year Ended December 31, 2021 And Provides Corporate Update
Via Benzinga
90 Biggest Movers From Yesterday
Via Benzinga
SciSparc And Clearmind Reveal Potential To Reduce Alcohol Consumption With Psychedelic Treatment In New Patent Application
Via Benzinga
SciSparc And Clearmind Medicine Inc. Collaboration Yields New Patent Application For Psychedelic Combination Treatment For Binge Behaviors
Via Benzinga
55 Biggest Movers From Friday
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
12 Stocks Halted On A Circuit Breaker This Week
Via Benzinga
36 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Mixed; US Pending Home Sales Index Drop 4.1%
Via Benzinga
Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice
Via Benzinga
Clearmind Medicine, SciSparc Launch A Psychedelic Pharma Collaboration
Via Benzinga
Meet a Company Harnessnessing the Power of Synergy for its Drug Therapeutics
Via Benzinga
SciSparc Has Been Granted The Patent in the United States for its Core Technology, Used to Treat Central Nervous System Disorders.
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
68 Biggest Movers From Yesterday
Via Benzinga
Advances for Tourette Syndrome, Alzheimer’s Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC)
Via Get News
Advances for Tourette Syndrome, Alzheimer's Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC) SPRC Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems
Via Viz Release
Topics Intellectual Property
Exposures Intellectual Property
Pharmaceutical company SciSparc Ltd to make progress in treating nervous system disorders in 2022
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.